田野，博士
教育经历：
2004－2008：浙江大学药学院，理学学士
2008－2013：浙江大学药学院，医学博士
2010－2011：美国华盛顿大学医学院，联合培养博士研究生
2014－2015：美国加州大学戴维斯分校，博士后
工作经历：
2013–2016：第四军医大学唐都医院，药学部
主管药师，从事药物分析、中药药物代谢方面的项目研究工作
2016至今：西北工业大学 生命学院助理教授，从事骨代谢相关研究
科研经历：
2014–2015：microRNA对药物代谢酶的调控--药物代谢
从基因、蛋白、活性三个层面研究microRNA对药物代谢酶的调控作用
2010–2013：CYP3A5介导的代谢激活引起的肺毒性--毒理学研究
建立了CYP3A5的肺源转基因细胞模型, 毒理学方法研究CYP3A5的代谢激活作用
2008–2012：创新药物研究开发技术平台--“十一五”重大专项
负责建立了LLC-PK1/BCRP转基因细胞模型筛选平台, 采用细胞双向转运以及摄取实验筛选BCRP的底物,LC-MS/MS方法检测样品
2010–2011：具有立体选择性的单克隆抗体的制备--国家自然科学基金
以细胞融合技术建立并筛选得到了可以分泌识别R-/S-构象的单克隆抗体的杂交瘤细胞, 用动物腹水法制备了相应的单克隆抗体
2007–2008：HS009临床前药效学药动学实验：横向课题
放射标记法进行大鼠体内的药动学实验,负责完成了部分实验及样品测定
2007–2008：荧光偏振法研究大黄酸和大黄素对P-糖蛋白的抑制作用机理
发表论文：
[1] Ye Tian, Shuijie Shen, Yan Jiang, Qi Shen, Su Zeng*, Jiang Zheng*. CYP3A5 mediates bioactivation and cytotoxicity of tetrandrine. Arch Toxicol. 2015 Aug 25 (IF=5.98).
[2] Ye Tian, Sainan Qian, Yan Jiang, Qi Shen, Jiang Zheng, Hui Zhou*, Su Zeng*. The interaction between human breast cancer resistance protein (BCRP) and five bisbenzylisoquinoline alkaloids. Int J Pharmaceut. 453(2), 371-379, 2013 (IF=3.78).
[3] Ye Tian, Yicong Bian, Yan Jiang, Sainan Qian, Aiming Yu, Su Zeng*. Interplay of Breast Cancer Resistance Protein (BCRP) and metabolizing enzymes. Curr Drug Metab, 16(10), 877-893, 2015 (IF=2.97).
[4] Ye Tian, Ying He, Haihong Hu, Lu Wang, Su Zeng*. Determination of the enantioselectivity of six chiral aryloxy aminopropanol drugs transport across Caco-2 cell monolayers. Acta Pharmaceutica Sinica B. 2(2), 168–173, 2012.
[5] 田野，屈伯宣，姚艳，曾苏*. LLC-PK1/BCRP细胞系的建立及其生物学特征. 药学学报. 第47卷，第12期，1599-1604页，2012.
[6] Ai-Ming Yu*, Ye Tian, Mei-Juan Tu, Pui Yan Ho, Joseph L. Jilek. MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy. Drug Metab Dispos, 44(3), 308-319, 2016 (IF=3.25).
[7] 屈伯宣，田野，余露山，蒋惠娣，周权，曾苏*. 体外细胞模型中氟伐他汀对映体的手性分离和含量测定方法学研究. 浙江大学学报(医学版). 第40卷，第1期，12-16页，2011.
[8] Shuijie Shen, Fan Zhang, Su Zeng, Ye Tian, Xiaojuan Chai, Shirley Gee, Bruce D. Hammock, Jiang Zheng*. Development of enantioselective polyclonal antibodies to detect styrene oxide protein adducts. Anal Chem. 81(7), 2668-2677, 2009 (IF=5.86).
[9] Siyuan Sun, Zhongjian Chen, Liping Li, Dongli Sun, Ye Tian, Hao Pan, Huichang Bi, Min Huang, Su Zeng, Huidi Jiang*. The two enantiomers of tetrahydropalmatine are inhibitors of P-gp, but not inhibitors of MRP1 or BCRP. Xenobiotica. 42(12), 1197-1205, 2012 (IF=1.79).
[10] Haihong Hu, Chen Su, Yan Jiang, Lushan Yu, Yao Liu, Ye Tian, Siyun Xu, Hui Zhou, Xin He, Huidi Jiang, Su Zeng*. Construction and application of double-transfected cells expressing the human transporter P-glycoprotein and cytochrome P450 3A4. Pharmazie. 68(10), 816-820, 2013 (IF=1.00).
[11] Li Li, Qingqing Yao, Siyun Xu, Haihong Hu, Qi Shen, Ye Tian, Lanying Pan, Hui Zhou, Huidi Jiang, Chuang Lu, Lushan Yu*, Su Zeng*. Cyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP. Eur J Pharm Biopharm. 88(3),759-767, 2014 (IF=4.24).
[12] Qi Shen, Minjuan Zuo, Li Ma, Ye Tian, Lu Wang, Huidi Jiang, Quan Zhou, Hui Zhou*, Lushan Yu*, Su Zeng. Demethylation of neferine in human liver microsomes and formation of quinone methide metabolites mediated by CYP3A4 accentuates its cytotoxicity. Chem Biol Interact. 224C: 89-99, 2014 (IF=2.89).
会议论文
[1] Ye Tian, Chun-Yi Wu, Joyce Lee, Kit S. Lam, Ai-Ming Yu*. Development and Validation of An LC-MS/MS Method for the Quantification of Doxorubicin and Doxorubicinol in Canine Plasma. 9th Annual Spotlight on Junior Investigators Cancer Research Mini-Symposium, UC Davis Comprehensive Cancer Center, Sacramento, CA95817, USA, 02 July, 2015.
[2] Xueliang Dang*, Yan Zhang, Lei Shi, Na Hu, Shun Guo, Jiepin Wang, Tao Sun, Ye Tian. Protection Mechanism of Glycyrrchizin to Acetaminophen-induced Liver Injury in Mice. 75th FIP World Congress of Pharmacy and Pharmaceutical Sciences 2015, Düsseldorf, Germany, 29 Septemb
科研基金项目：
1.中国博士后科学基金面上项目：“MACF1调节细胞氧化还原平衡参与模拟失重抑制成骨分化”（No.2017M613210）
